Table 5 Propensity-matched comparison of study patients who did or did not receive HES before or after cardiopulmonary bypass

Preoperative parameters

 Number of patients

481

962

 Age (years)

65.9 ± 13.2

66.2 ± 12.2

2.74

 Male gender

292 (60.7%)

581 (60.4%)

0.65

 Body mass index (kg/m²)

23.1 ± 3.8

22.9 ± 3.2

0.49

 Preoperative creatinine (mg/dL)

0.92 ± 0.40

0.93 ± 0.40

2.17

 Emergency

180 (37.4%)

369 (38.4%)

−1.99

  Hypertension

289 (60.0%)

587 (61.0%)

−1.96

  Diabetes mellitus

68 (14.1%)

142 (14.8%)

−2.52

  Chronic obstructive pulmonary disease

12 (2.5%)

23 (2.4%)

2.18

  Chronic heart failure

192 (39.9%)

383 (39.8%)

0.22

  Atrial fibrillation

113 (23.5%)

232 (24.1%)

−1.72

  1

10 (2.1%)

20 (2.1%)

  2

296 (61.5%)

553 (57.5%)

  3

143 (29.7%)

314 (32.6%)

  4

26 (5.4%)

72 (7.5%)

  5

6 (1.2%)

3 (0.3%)

  Angiotensin-converting-enzyme inhibitors

82 (17.0%)

170 (17.7%)

−2.17

  Angiotensin II receptor blockers

168 (34.9%)

341 (35.4%)

−1.14

 HES (mL)

692 ± 387

–

 Hespander® (mL)

14 ± 104

 Salinhes® (mL)

627 ± 432

 Voluven® (mL)

50 ± 186

 Crystalloids (mL)

2524 ± 1627

2553 ± 1129

2.06

 Red blood cells (mL)

457 ± 959

511 ± 858

5.84

 Fresh frozen plasma (mL)

392 ± 628

440 ± 653

7.60

 Platelet concentrates (mL)

102 ± 193

112 ± 192

4.99

 Estimated blood loss (mL)

669 ± 656

715 ± 681

6.82

 Urinary outputs (mL)

1387 ± 884

1391 ± 846

0.48

 Operative time (min)

356 ± 124

364 ± 116

7.16

 Cardiopulmonary bypass time (min)

170 ± 67

173 ± 61

5.53

 Longest interval of mABP < 65 (min)

66 ± 54

67 ± 53

1.92

 Total mABP < 65 duration (min)

210 ± 107

215 ± 114

5.09

  On-pump CABG

8 (1.7%)

14 (1.5%)

  Valve surgeries

261 (54.3%)

489 (50.8%)

  Valve + CABG

34 (7.1%)

93 (9.7%)

  Major aortic surgeries

152 (31.6%)

316 (32.8%)

  Others

26 (5.4%)

50 (5.2%)